We were all addicted to the transparency of Nader and the frequent news updates. Not all I guess but I would venture to say the majority liked to be updated.

Looks like we will be like other stocks now with quarterly or biannually updates and only SEC filings. Going to be a little less chatting on the boards. Half the people will fall off the boards now with nothing to really talk about. No news will mean less to chat about.

I still believe in Leronlimab and will not sell a share. As Scott Kelly said… commercialization of our platform drug with a new CEO. Funny how the new board was the coop. It will be interesting to see if partnership / buy-out or new CEO first.